DOI: 10.36347/sjams.2023.v11i12.016

Pages: 2090-2094

Background: Tamoxifen, a non-steroidal triphenylethylene estrogen antagonist, serves as a crucial therapy, both alone and in conjunction with other treatments, for disseminated breast carcinomas due to its proven efficacy and minimal adverse effects in oncology. Despite its extensive use, ocular toxicity reports linked to tamoxifen remain relatively scarce in available literature. Given the limited studies in the Bangladeshi context, this investigation aims to explore ocular manifestations in breast cancer patients undergoing prolonged low-dose tamoxifen therapy for over two years. Methods: This longitudinal study was conducted at Dhaka Medical College Hospital between October 2019 and July 2020, involving 45 patients undergoing low-dose tamoxifen treatment for more than two years post-surgical intervention for breast carcinoma. Detailed patient histories were obtained, and thorough ophthalmic examinations were performed for each participant. Data were meticulously recorded in separate case files and analyzed using SPSS 22 to ensure accuracy and reliability. Observations and Results: The average age of the patients was 51.16 (±8.82) years, and 11.10% of the respondents exhibited ocular manifestations. These manifestations primarily comprised cataracts (6.70%), retinitis (2.20%), and optic neuritis (2.20%). Regarding eye-related conditions, cataracts are evident in patients 01, 02, and 03, while retinitis is observed in patients 04 and 05. Optic neuritis is specifically noted in patient 05. The data highlights occurrences of these conditions in relation to the duration of Tamoxifen treatment and the patients' ages, potentially suggesting associations worthy of further exploration regarding the impact of Tamoxifen on eye health in this demographic. Conclusion: This study revealed that approximately one-tenth of the patient cohort undergoing tamoxifen therapy for over two years experienced ocular manifestations. However, further in-depth investigations are strongly ...